Topics of Interest

An Update from the International Guillain-Barre Study (IGOS) by Dr. Bart Jacobs

The IGOS-1000 cohort has now been tested for the main preceding infections and is currentlytested for antibodies extensively. We have also recently finalized a study in IGOS on theassociation between GBS and SARS-CoV-2 during the first 3 months of the pandemic. In myview this study shows the importance of having an ongoing global prospective study…

Read More about An Update from the International Guillain-Barre Study (IGOS) by Dr. Bart Jacobs

50 To Forward

This year, we are strengthening our advocacy efforts and putting out a call for a leader in each of the 50 states! These 50 leaders will help us push our goals FORWARD! Here is what we expect from our advocacy leaders: Be informed about all of our advocacy priorities, especially our policy priority of creating…

Read More about 50 To Forward

Welcome, New Congress!

As we kicked off 2021 full of hope for the future, we also welcomed a new Congress to Capitol Hill. The 117th Congress first convened on January 3, 2021, and now that they are settled in, we believe it is time for the GBS|CIDP and variants community to reach out and introduce our Representative and…

Read More about Welcome, New Congress!

GBS|CIDP Foundation International continues to work with FDA on GBS|CIDP patient concerns

After holding a GBS Patient Listening session with the FDA in the Summer of 2020, the Foundation has continued to work with key leadership at the FDA to continue bringing the patient voice to their current work. The FDA holds a very special role in the US healthcare system. Their job is to review and…

Read More about GBS|CIDP Foundation International continues to work with FDA on GBS|CIDP patient concerns